Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (10)

2020

  1. Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1866, Núm. 5

2018

  1. Chemoresistance and chemosensitization in cholangiocarcinoma

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1444-1453

  2. Genetic heterogeneity of SLC22 family of transporters in drug disposition

    Journal of Personalized Medicine, Vol. 8, Núm. 2

  3. Molecular bases of the poor response of liver cancer to chemotherapy

    Clinics and Research in Hepatology and Gastroenterology

2017

  1. Molecular bases of chemoresistance in cholangiocarcinoma

    Current Drug Targets, Vol. 18, Núm. 8, pp. 889-900

2016

  1. Protective role of biliverdin against bile acid-induced oxidative stress in liver cells

    Free Radical Biology and Medicine, Vol. 97, pp. 466-477

2013

  1. Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis

    Bioorganic and Medicinal Chemistry, Vol. 21, Núm. 14, pp. 4432-4441

2012

  1. Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins

    Molecular Pharmaceutics, Vol. 9, Núm. 9, pp. 2565-2576

  2. No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors

    Molecular Pharmaceutics, Vol. 9, Núm. 6, pp. 1693-1704

  3. Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy

    Pharmacological Research, Vol. 66, Núm. 5, pp. 419-427